Cerebral hemodynamic changes at high altitude in adults: a systematic review and meta-analysis of transcranial Doppler and duplex ultrasound studies.

J Appl Physiol (1985)Jul 22, 2026 (epub)
Clinical ResearchNeurology

J Pierre Zila-Velasque, Pamela Grados-Espinoza, Sebastian Abanto-Urbano et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated cerebral hemodynamic changes in adults exposed to altitudes of 1,500 m or higher. Analyzing 55 studies with 1,935 participants, the research found significant reductions in mean cerebral artery velocity (MD -5.79 cm/s) and volumetric blood flow (MD -32.99 mL/min) among other parameters, highlighting the variability in responses between native high-altitude populations and lowlanders.

Key findings

  • Altitude exposure reduced mean cerebral artery velocity by 5.79 cm/s.
  • Volumetric blood flow decreased by 32.99 mL/min at high altitude.
  • Cerebral oxygen saturation was lower by 4.45% in high-altitude conditions.
  • Substantial heterogeneity was observed across different outcomes.

Why it matters

Understanding the impact of high altitude on cerebral hemodynamics is crucial for clinicians managing patients in or traveling to elevated regions. The findings emphasize the need for tailored approaches based on population-specific adaptations to hypoxia.

Source

Published in J Appl Physiol (1985). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.